Angiotensin converting enzyme inhibitors and type angiotensin II receptor blockers
Medical > Therapy > General measures
Angiotensin converting enzyme inhibitors and type angiotensin II receptor blockers
Angiotensin II is a potent vasoconstrictor of the pulmonary vessels. In healthy volunteers, pre-treatment with either an angiotensin converting enzyme (ACE) inhibitor or a type 1 angiotensin II receptor blocker inhibit the acute response of the pulmonary circulation to hypoxia. However, both vasodilators produce a significant fall in systemic artery pressure (Cargill and Lipworth, 1996, Kiely et al., 1995). Contradictory results are reported in patients with hypoxemic cor pulmonale. In 15 COPD patients, captopril, a short half-life ACE inhibitor, did not decrease pulmonary artery pressure (Zielinski et al., 1986), whereas in other 9 patients, losartan, an angiotensin II receptor blocker significantly decreased both mean pulmonary artery pressure and total pulmonary vascular resistance (Kiely et al., 1997) compared to placebo. Presently, there is no data on the effects of ACE inhibitors or angiotensin II receptor blockers, therefore, they can not be recommended for the treatment of pulmonary hypertension in patients with non-hypoxemic pulmonary hypertension.
References
Back to > Medical > Therapy > General measures
Angiotensin converting enzyme inhibitors and type angiotensin II receptor blockers
Angiotensin II is a potent vasoconstrictor of the pulmonary vessels. In healthy volunteers, pre-treatment with either an angiotensin converting enzyme (ACE) inhibitor or a type 1 angiotensin II receptor blocker inhibit the acute response of the pulmonary circulation to hypoxia. However, both vasodilators produce a significant fall in systemic artery pressure (Cargill and Lipworth, 1996, Kiely et al., 1995). Contradictory results are reported in patients with hypoxemic cor pulmonale. In 15 COPD patients, captopril, a short half-life ACE inhibitor, did not decrease pulmonary artery pressure (Zielinski et al., 1986), whereas in other 9 patients, losartan, an angiotensin II receptor blocker significantly decreased both mean pulmonary artery pressure and total pulmonary vascular resistance (Kiely et al., 1997) compared to placebo. Presently, there is no data on the effects of ACE inhibitors or angiotensin II receptor blockers, therefore, they can not be recommended for the treatment of pulmonary hypertension in patients with non-hypoxemic pulmonary hypertension.
References
Back to > Medical > Therapy > General measures
Druckversion
Suche
SSPH Research Prize 2012
Deadline for submission: April 30, 2012
Further information
Symposium "pulmonal-arterielle Hypertension im Kindesalter"
Donnerstag, 10. Mai 2012, 16.00-18.00, Bern
Further information:
5th International Congress of the Swiss Society of Pulmonary Hypertension (SSPH)
28.-29. September 2012, Thun, Congress Hotel Seepark Thun
Informationen: www.imk.ch/sgph2012
mehr